Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time. This week we sit down with Kim Sanchez Rael Fast onset economics The nano problem Science/ AI and so much more
Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time.
This week we sit down with Kim Sanchez Rael
Fast onset economics
The nano problem
Science/ AI and so much more
Fast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product.
Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier.
The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change.
Topics include:
Learn more about Azuca and TiME INFUSION® at https://azuca.co/.
Guest: Kim Sanchez Rael, President and CEO, Azuca
Host: Bryan Fields, The Dime
Chapters
Our Links
Follow The Dime for more conversations on cannabis business, operations, and international markets.
Share this episode with an operator rethinking their edibles.
Guest Links